XTRA:BAYNPharmaceuticals
Is Bayer (XTRA:BAYN) Still Undervalued After Its Health Canada Approval?
Health Canada approval puts Bayer stock in focus
Bayer (XTRA:BAYN) is back on investors’ radar after Health Canada expanded the indication for LYNKUET to treat moderate to severe vasomotor symptoms linked to adjuvant endocrine therapy in breast cancer.
The approval, supported by the OASIS-4 study, gives Bayer the first authorized treatment option in Canada for this specific patient group. This development could prompt investors to reassess the company’s pharmaceuticals footprint alongside its...